# DSIP FAQ — Delta Sleep-Inducing Peptide Research Questions Answered > Frequently asked questions about DSIP (Delta Sleep-Inducing Peptide): mechanism, clinical trial findings, FDA status, half-life, withdrawal evidence, and the limits of the current research record. The most common questions about DSIP — answered with what the published literature actually shows. ## Research Questions **What is DSIP and what does the research literature show?** DSIP (Delta Sleep-Inducing Peptide, also designated Emideltide) is a nonapeptide — nine amino acids, sequence WAGGDASGE — first isolated from rabbit cerebral venous blood in 1974 by Schoenenberger and Monnier while studying electrically-induced slow-wave sleep [1]. The research literature spans five decades and covers sleep architecture, opioid and alcohol withdrawal alleviation, chronic pain, anticonvulsant effects, growth hormone release, antioxidant biology in aging, mitochondrial protection under hypoxia, and stroke recovery. The record is genuinely broad, which is unusual for a single research peptide — and the breadth has both scientific and interpretive implications. The evidence is real, but most of it comes from small pilot studies that have not been replicated in modern large trials. --- **How does Delta Sleep-Inducing Peptide actually work in the brain?** DSIP does not appear to act through a single identified receptor. Research points to several converging pathways: inhibitory modulation of NMDA receptors (which regulate neuronal excitability), potentiation of GABA-A receptors (the brain's primary inhibitory system), normalization of HPA axis signaling with reduced basal ACTH and cortisol, dopaminergic mediation of growth hormone release, interaction with the endogenous opioid system via met-enkephalin stimulation, and upregulation of antioxidant enzymes [1, 8]. The amphiphilic structure of the peptide facilitates crossing the blood-brain barrier via a saturable, high-affinity carrier mechanism — which is how it reaches CNS targets at all [1]. What's notable is how many different systems DSIP appears to modulate, and how incomplete the mechanistic picture still is: no dedicated receptor has been identified. --- **What have clinical studies found about DSIP for insomnia?** The human insomnia data comes from a series of small pilot studies by Schneider-Helmert and colleagues in the 1980s. At 25 nmol/kg intravenously, DSIP improved sleep efficiency and reduced sleep latency versus placebo in double-blind crossover designs [15]. A seven-night study in 14 middle-aged chronic insomniacs showed improvements from the first dose, with sleep efficiency reaching normal-control levels and daytime alertness improving significantly [3]. One study in six chronic insomniacs reported extended sleep duration, improved continuity, slightly increased REM, and no daytime adverse effects [2]. Effect sizes were generally described as modest by the authors, and some subjective sleep ratings did not change significantly [15]. The absence of large, modern, pre-registered replication trials means these findings are hypothesis-generating rather than conclusive. --- **What does the research say about DSIP for opioid and alcohol withdrawal?** The withdrawal data is the most striking in the DSIP human literature. A 1983 study by Dick, Grandjean, and Tissot administered DSIP at 25 nmol/kg intravenously to 67 patients — 28 alcohol-dependent and 39 opioid-dependent — experiencing acute withdrawal [4]. Somatic withdrawal signs were alleviated in 48 of 49 evaluable subjects, a 98% rate, with immediate onset and no major adverse events. Psychological symptoms such as anxiety resolved more gradually over hours. The authors attributed the rapid somatic effect to DSIP's interaction with opioid receptor systems and met-enkephalin release. This data has not been independently replicated in a Western regulatory-grade trial. The FDA's scheduling of a formal PCAC review for Emideltide in July 2026 includes opioid withdrawal among the compounding indications under consideration. --- **What is the current regulatory status of DSIP (Emideltide)?** DSIP is not approved for any therapeutic indication by the FDA. Under the INN Emideltide, it was placed on the FDA's Category 2 bulk drug substances list in September 2023, meaning it is not eligible for pharmacy compounding under Section 503A at that time, with the FDA citing immunogenicity as a primary concern. A formal reassessment is scheduled at the Pharmacy Compounding Advisory Committee (PCAC) on July 24, 2026 (docket FDA-2025-N-6895). The PCAC will evaluate whether Emideltide should be added to the Section 503A Bulk Drug Substances List for compounding use in opioid withdrawal, chronic insomnia, and narcolepsy. The outcome is not predetermined — inclusion on the 503A list would expand compounding access; exclusion or confirmation of Category 2 status would maintain the current restriction. --- **Are there recent studies on DSIP from 2021 to 2024?** Yes. Two significant research publications emerged in this period: - **Tukhovskaya et al. (2021, *Molecules*): Intranasal DSIP and stroke recovery.** Administered at 120 micrograms/kg intranasally before MCAO focal stroke and for 7 post-reperfusion days in rats, DSIP normalized motor function on the rotarod by day 7, despite comparable infarct volumes between treated and vehicle groups — suggesting a neurorestorative rather than neuroprotective mechanism [14]. - **Mu et al. (2024, *Frontiers in Pharmacology*): Pichia pastoris-expressed DSIP-CBBBP fusion.** A DSIP peptide engineered with a BBB-crossing sequence expressed via yeast reduced daily wakefulness by 31% in a PCPA-induced insomnia mouse model (p<0.0001), outperformed native DSIP and GABA separately, restored serotonin, melatonin, and dopamine levels, reduced anxiety on the elevated plus maze, and reversed hippocampal neuron density loss [17]. The 2024 fusion study is particularly significant because it addresses the parent peptide's main pharmacokinetic limitation — the short half-life from aminopeptidase degradation — with a validated bioengineering approach. --- **What are the main controversies and limitations in the DSIP research record?** Several issues limit how strongly conclusions can be drawn from the existing data: - No gene encoding DSIP in rabbits or humans has been identified; no dedicated receptor has been characterized [1]. - Most human trials involve 6-67 subjects and were conducted in the 1980s without modern trial standards. - Sleep-promoting effects are inconsistent across studies — some show significant delta-wave increases, others do not [1]. - Plasma DSIP-like immunoreactivity does not reliably distinguish sleep-disorder patients from controls, limiting biomarker utility [16]. - Eastern European clinical data (particularly Deltaran geroprotective findings) have not been independently replicated in Western regulatory trials. - The short in vitro brain half-life (~15 minutes) raises unanswered questions about bioavailability from non-IV routes without structural modification. - Long-term human safety data is absent. --- **Does DSIP have effects beyond sleep?** The research suggests yes. Animal and small human studies have explored anticonvulsant effects in a rat epilepsy model [7], growth hormone stimulation via hypothalamic dopaminergic mediation [8, 9], luteinizing hormone release without FSH effect [12], opioid and alcohol withdrawal alleviation in humans [4], chronic pain reduction in a small pilot study [5], antioxidant enzyme upregulation in aging rats [13], mitochondrial respiratory protection under hypoxia [10], and post-stroke motor function recovery in rats [14]. These findings span multiple systems — sleep, endocrine, stress response, antioxidant biology, neuroprotection — which may reflect DSIP's convergent multi-pathway mechanism, or may indicate that some effects are indirect consequences of sleep-architecture normalization, or may simply reflect the broad exploratory character of early peptide pharmacology. Disentangling these possibilities is one of the unfinished jobs of the DSIP literature. --- **What is DSIP's half-life and why does it matter?** The estimated in vitro brain half-life of native DSIP is approximately 15 minutes, due to aminopeptidase-mediated cleavage of the N-terminal tryptophan residue [1]. In practice, this means the peptide is rapidly degraded in brain tissue after delivery. This creates an interpretive puzzle: how can a 15-minute half-life peptide produce sleep effects lasting hours? The answer is not fully resolved in the literature. The phosphorylated analog DSIP-P is markedly more stable and potent than the parent peptide, and the 2024 bioengineered fusion peptide approach [17] demonstrated that overcoming this degradation barrier substantially amplifies DSIP-class activity. --- **What is the peptide sequence of DSIP and why does sequence specificity matter?** DSIP's amino acid sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, abbreviated WAGGDASGE [1]. Structure-activity studies showed that single amino acid substitutions within this sequence completely abolished sleep-inducing activity in animal models [1]. This high sequence-specificity means the observed effects are not simply a consequence of any amphiphilic peptide reaching the CNS — the specific sequence is required. It also implies that any structural modification (such as phosphorylation at the N-terminal, or fusion with a BBB-crossing peptide) must be designed carefully to preserve the active conformation. --- **Is DSIP related to melatonin or other sleep compounds?** DSIP and melatonin appear to operate on complementary arms of circadian sleep regulation. DSIP administration increases endogenous melatonin levels in research models [1], which has led some researchers to hypothesize an additive or synergistic relationship between the two systems. A 2024 PCPA-insomnia mouse study confirmed that DSIP-class administration restored melatonin levels alongside serotonin and dopamine [17]. DSIP's mechanism, however, is distinct from melatonin's — DSIP acts through NMDA inhibition, GABA-A potentiation, opioid system engagement, and HPA normalization, while melatonin acts primarily on MT1 and MT2 receptors to entrain circadian phase. The two compounds are not interchangeable in research contexts. --- **Has DSIP been studied in narcolepsy?** Yes, in a case report context. Schneider-Helmert (1984) documented repeated DSIP injections in a 35-year-old male narcoleptic, observing reduced daytime sleep attack frequency, improved alertness and performance, and normalization of polysomnographic architecture — with compressed total sleep duration and enhanced REM [11]. Plasma DSIP-like immunoreactivity measurements in a group of narcolepsy patients (n=10), sleep apnea patients (n=9), and normal controls (n=11) found no statistically significant differences between groups, though a trend toward lower DSIP-LI was observed in unmedicated narcoleptic patients [16]. Narcolepsy is among the indications under review by the FDA's PCAC for potential Emideltide compounding use in July 2026. --- **Is DSIP listed on the WADA prohibited list?** DSIP is not named specifically on the current WADA Prohibited List. However, as an unapproved peptide hormone or related substance, it would likely fall under the S0 category (Non-Approved Substances) — covering any pharmacological substance that has no current approval by a governmental regulatory health authority and is not included in any other WADA category. Athletes subject to anti-doping regulations should consult the current WADA Prohibited List and their sport's governing body before any research-related exposure to DSIP. --- An indexed editorial digest of the peer-reviewed DSIP research record — not clinical guidance, not a vendor.